| (210) | Number of the EPO application | 18720895 |
| (220) | Filing date of the EPO application | 2018.04.09 |
| (80) | EPO patent specification publication (B) | EPB nr. 41/2022, 2022.10.12 |
| (110) | EPO patent number | 3609497 |
| (11) | Number of the document | MD 3609497 T2 |
| (21) | Number of the application | e 2020 0190 |
| (71) | Name(s) of applicant(s), code of the country | JANSSEN PHARMACEUTICA NV, BE; |
| (72) | Name(s) of inventor(s), code of the country | YU Margaret K., US;
SNYDER Linda Anne, US; |
| (73) | Name(s) of owner(s), code of the country | JANSSEN PHARMACEUTICA NV, BE; |
| (54) | Title of the invention | Niraparib, abiraterone acetate and prednisone for treating prostate cancer |
| (13) | Kind-of-document code | T2 |
| (51) | International Patent Classification | A61K 31/454 (2006.01.01); A61K 31/573 (2006.01.01); A61K 31/58 (2006.01.01); A61P 35/00 (2006.01.01) |
| (19) | Country | BE |
| (41) | Date of publication of the application | 2020.03.31 |
| (49) | Date of publication of the translation of the validated European patent specification | 2023.03.31 |
| (30) | Priority | 201762485164 P, 2017.04.13, US |
| (74) | Patent attorney | (Procedură) PARASCA Dumitru, str. Eminescu nr. 40, ap. 13, c/p 28, MD-2012, Chişinău, Republica Moldova |
| (86) | International application | PCT/US2018/026661, 2018.04.09 |
| (87) | International publication | WO 2018/191141, 2018.10.18 |